SPINRAZA
Spinraza (nusinersen sodium) is an antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA). The therapy is approved for use in both pediatric and adult patient populations. It is specifically designed to treat SMA associated with mutations in chromosome 5q that lead to a deficiency in survival motor neuron (SMN) protein.
How SPINRAZA Works
Spinraza is an antisense oligonucleotide that targets survival motor neuron-2 (SMN2) messenger ribonucleic acid (mRNA) transcripts. The drug increases the inclusion of exon 7 in these transcripts, which allows for the production of full-length SMN protein. By increasing the levels of this protein, the medication addresses the deficiency caused by chromosome 5q mutations.
Details
- Status
- Prescription
- First Approved
- 2016-12-23
- Routes
- INTRATHECAL
- Dosage Forms
- SOLUTION
SPINRAZA Approval History
What SPINRAZA Treats
2 indicationsSPINRAZA is approved for 2 conditions since its original approval in 2016. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Spinal muscular atrophy (SMA) in pediatric patients
- Spinal muscular atrophy (SMA) in adult patients
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
SPINRAZA FDA Label Details
ProIndications & Usage
FDA Label (PDF)SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients
SPINRAZA Patents & Exclusivity
Patents (20 active)
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.